VM-26 and dimethyl triazeno imidazole carboxamide in Ewing's sarcoma.
Twenty-seven patients with biopsy proven Ewing's sarcoma were randomised to receive one of two adjuvant chemotherapy regimens for two years. Group A were given monthly courses of vincristine, adriamycin and dimethyl triazeno imidazole carboxamide (DIC); Group B received monthly courses of VM-26, adriamycin and DIC. Chemotherapy was commenced after biopsy confirmation of disease. The primary tumour was treated with irradiation to 3,000-5,000 rad and by resection in three patients. With a median follow-up of 26 months, 52% of patients are disease free. Ten patients died, seven from recurrent disease and three from complications of treatment. There was a significant difference in disease free survival rate of patients with long bone lesions (11/12) compared with patients with flat bone lesions (6/15). The disease free survival rate of Groups A and B was similar. Our results suggest that in combination chemotherapy for Ewing's sarcoma, vincristine and VM-26 have similar anti-tumour activity.
D000293:Adolescent; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011897:Random Allocation; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000401:mortality; D013713:Teniposide / Q000008:administration & dosage / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D013713:Teniposide; D011034:Podophyllotoxin